Toronto - Delayed Quote CAD

Bausch Health Companies Inc. (BHC.TO)

Compare
11.38
-0.23
(-1.98%)
At close: January 10 at 4:00:00 PM EST
Loading Chart for BHC.TO
DELL
  • Previous Close 11.61
  • Open 11.47
  • Bid 11.36 x --
  • Ask 11.37 x --
  • Day's Range 11.26 - 11.57
  • 52 Week Range 5.45 - 15.43
  • Volume 266,874
  • Avg. Volume 275,415
  • Market Cap (intraday) 4.27B
  • Beta (5Y Monthly) 0.75
  • PE Ratio (TTM) --
  • EPS (TTM) -0.68
  • Earnings Date Feb 20, 2025 - Feb 24, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Nov 10, 2010
  • 1y Target Est 8.05

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

www.bauschhealth.com

20,270

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BHC.TO

View More

Performance Overview: BHC.TO

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

BHC.TO
2.43%
S&P/TSX Composite index
0.60%

1-Year Return

BHC.TO
2.06%
S&P/TSX Composite index
18.10%

3-Year Return

BHC.TO
66.70%
S&P/TSX Composite index
17.47%

5-Year Return

BHC.TO
68.89%
S&P/TSX Composite index
43.70%

Compare To: BHC.TO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BHC.TO

View More

Valuation Measures

As of 1/9/2025
  • Market Cap

    4.27B

  • Enterprise Value

    34.16B

  • Trailing P/E

    --

  • Forward P/E

    1.93

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.31

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.51

  • Enterprise Value/EBITDA

    8.95

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -1.88%

  • Return on Assets (ttm)

    4.15%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    9.47B

  • Net Income Avi to Common (ttm)

    -178M

  • Diluted EPS (ttm)

    -0.68

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    719M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    1.41B

Research Analysis: BHC.TO

View More

People Also Watch